A Phase I Multi-Institutional Study of Systemic Sorafenib in Conjunction with Regional Melphalan for In-Transit Melanoma of the Extremity

@article{Beasley2012API,
  title={A Phase I Multi-Institutional Study of Systemic Sorafenib in Conjunction with Regional Melphalan for In-Transit Melanoma of the Extremity},
  author={Georgia M Beasley and Andrew P. Coleman and Alan Michael Raymond and Gretchen M. Sanders and M. Angelica Selim and Bercedis L. Peterson and Mary S Brady and Michael A. Davies and Christi K Augustine and Douglas S. Tyler},
  journal={Annals of Surgical Oncology},
  year={2012},
  volume={19},
  pages={3896-3905}
}
BackgroundIsolated limb infusion with melphalan (ILI-M) corrected for ideal body weight (IBW) is a well-tolerated treatment for patients with in-transit extremity melanoma with an approximate 29 % complete response (CR) rate. Sorafenib, a multi-kinase inhibitor, has been shown to augment tumor response to chemotherapy in preclinical studies.MethodsA multi-institutional, dose-escalation, phase I study was performed to evaluate the safety and antitumor activity of sorafenib in combination with… CONTINUE READING
BETA

References

Publications referenced by this paper.
SHOWING 1-10 OF 39 REFERENCES

Similar Papers

Loading similar papers…